The GLOW Blend: What’s In It and the Research on Each Component

What is the GLOW blend?

The GLOW blend — listed in the catalogue as “GLOW 70 mg” — is the name for a research preparation that supplies three peptides together: GHK-Cu, BPC-157 and TB-500. That is a naming and composition fact only: the label records which three sequences are in the preparation, not that they act together and not that the trio has been studied as a unit. It is one of several multi-peptide research blends in the catalogue, and the word “GLOW” is a product name rather than a description of any effect.

Because the honest evidence for this preparation is the evidence for its three components, the rest of this page summarises each briefly and hands off to its full research page, then states plainly what the literature does — and does not — say about the three together.

The three components

GHK-Cu

GHK-Cu is the copper(II) complex of the naturally occurring tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys), first isolated from human plasma by Pickart and Thaler in 1973. Its literature is pleiotropic — no single receptor — and a distinctive strand is gene-expression profiling; the mechanisms examined include matrix-remodeling and antioxidant gene sets and fibroblast behaviour, studied largely in vitro, computationally and in animal models. For the full chemistry and mechanism detail, see GHK-Cu research: copper peptide mechanism. This is a neutral summary of what was studied, not a cosmetic or skin claim.

BPC-157

BPC-157 is a synthetic 15-amino-acid pentadecapeptide, a fragment of a gastric-juice protein first characterised in 1993. It is described as pleiotropic, with studies examining VEGFR2-associated angiogenesis, the nitric-oxide system and ERK1/2 signalling in model systems; the evidence base is overwhelmingly preclinical. For the full detail, see BPC-157 research: mechanism & studies. A neutral summary only.

TB-500 (thymosin β4)

TB-500 is a synthetic peptide corresponding to the actin-binding region of thymosin β4, a 43-amino-acid peptide. The best-characterised biochemistry is G-actin sequestration; the wider literature is pleiotropic and predominantly preclinical. For the full detail, see TB-500 research: thymosin β4 mechanism.

Is there research on the combination itself?

Stated plainly, because it is the point that matters most: the published literature studies GHK-Cu, BPC-157 and TB-500 separately. There is essentially no dedicated, peer-reviewed research on the three administered as a single combination — no controlled study establishing what the trio does as a unit, and none comparing the blend against any component on its own.

Combining the three sequences into one research preparation is therefore a formulation and catalogue decision, not a finding. This page makes no claim that the three do anything together, and no claim that the blend outperforms any component. The three component pages above are the actual evidence base — and each of them is, on its own terms, largely preclinical.

It is worth being explicit about why the honest answer is “essentially none” rather than simply “not summarised here.” Peer-reviewed peptide research is built around single, defined molecules studied in isolation, so that any observed effect can be attributed to one compound; a multi-peptide blend is instead assembled at the catalogue and formulation stage. A study of GHK-Cu, BPC-157 and TB-500 given together would be a separate piece of work with its own design and controls, and no such study exists in a form this page could responsibly cite. The most accurate statement is the one the three component summaries above already make: each molecule has its own distinct, and largely preclinical, literature, and the “GLOW” label groups them without adding a shared evidence base of its own.

Blend vs separate vials — a formulation fact

The catalogue lists GLOW 70 mg in two forms: as a co-formulated blend, and as separate vials of the three peptides. That is a packaging and formulation description — one vial versus three — and an identity fact, not a protocol or a ratio presented as a regimen. The milligram figure on the label is a catalogue quantity that identifies the material, not a dose, and this page gives no per-use amount, timing, or administration detail.

Research-grade sourcing and verification

For laboratory research use only, the GLOW preparation is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation. For a multi-peptide preparation that includes a copper complex, per-sequence identity — and, for the copper tripeptide, copper content and stoichiometry — are part of a reproducible material. Check the exact batch on the self-serve verify tool, and see how to read a COA for what the certificate reports. Sourcing and quality-assurance framing only.

Frequently asked questions

Literature cited

1. Pickart L, Thaler MM. “A tripeptide in human serum that stimulates growth/survival of hepatoma and normal liver cells” (isolation of GHK). 1973. (GHK-Cu component.)
2. Pickart L, Vasquez-Soltero JM, Margolina A. “GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.” BioMed Research International. 2015 (PMC4508379). (GHK-Cu component.)
3. Pickart L, Margolina A. “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.” Int. J. Molecular Sciences. 2018 (PMID 29986520). (GHK-Cu component.)
4. Chang C-H, et al. “The promoting effect of pentadecapeptide BPC 157 on tendon fibroblasts.” 2011 (PMC6271067). (BPC-157 component.)
5. Carlier MF, Jean C, Rieger KJ, Lenfant M, Pantaloni D. “Modulation of the interaction between G-actin and thymosin β4 by the ATP/ADP ratio.” PNAS. 1993;90(11):5034–5038. (TB-500 component.)
6. “Thymosin beta-4 and TB-500 in tissue healing, regeneration, and musculoskeletal repair: a scoping review.” Applied Sciences. 2026. (TB-500 component.)